MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, CHRS made $42,172K in revenue. $168,024K in net income. Net profit margin of 398.43%.

Income Overview

Revenue
$42,172K
Net Income
$168,024K
Net Profit Margin
398.43%
EPS
$1.43
Unit: Thousand (K) dollars
Revenue Breakdown
    • Toripalimab
    • Product And Service Other

Income Statement
2025-12-31
Net revenue
42,172
Cost of goods sold
13,814
Research and development
108,888
Selling, general and administrative
100,604
Total costs and expenses
223,306
Loss from operations
-181,134
Interest expense
9,001
Loss on debt extinguishment
0
Other income (expense), net
7,011
Loss from continuing operations before income taxes
-183,124
Net loss from continuing operations
-183,124
Net revenue
76,613
Cost of goods sold
26,755
Research and development
521
Selling, general and administrative
11,096
Total costs and expenses
38,372
Income from operations
38,241
Interest expense
3,484
Gain on sale transactions, net
338,315
Loss on debt extinguishment
-10,286
Other income (expense), net
-11,638
Net income from discontinued operations before income taxes
351,148
Net income from discontinued operations, net of tax (note 6)
351,148
Net income
168,024
Basic EPS
1.43
Diluted EPS
1.43
Basic Average Shares
117,143,457
Diluted Average Shares
117,143,457
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net revenue$76,613K Gain on saletransactions, net$338,315K Income from operations$38,241K Total costs andexpenses$38,372K Net income fromdiscontinued operations...$351,148K Other income(expense), net-$11,638K Loss on debtextinguishment-$10,286K Interest expense$3,484K Cost of goods sold$26,755K Selling, general andadministrative$11,096K Research and development$521K Net income fromdiscontinued operations, net...$351,148K Net income$168,024K Net loss fromcontinuing operations-$183,124K Loss from continuingoperations before income...-$183,124K Other income(expense), net$7,011K Toripalimab$40,836K Product And ServiceOther$1,336K Loss from operations-$181,134K Interest expense$9,001K Net revenue$42,172K Total costs andexpenses$223,306K Research and development$108,888K Selling, general andadministrative$100,604K Cost of goods sold$13,814K

Coherus Oncology, Inc. (CHRS)

Coherus Oncology, Inc. (CHRS)